Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

Fig. 2

Serial changes in estimated glomerular filtration rate (eGFR) at 2 years before and after starting sodium–glucose cotransporter 2 (SGLT2) inhibitor in participants with type 2 diabetes and chronic kidney disease in three groups: normoalbuminuria (A1; n = 46), microalbuminuria (A2; n = 25), and macroalbuminuria (A3; n = 16). *P < 0.05 vs. A3, one-way analysis of variance followed by post hoc Bonferroni test

Back to article page